Selected publications
-
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Clinical Cancer Research.
2006
Academic Article
GET IT
Times cited: 21 -
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Clinical Cancer Research.
2004
Academic Article
GET IT
Times cited: 55 -
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Clinical Cancer Research.
2003
Academic Article
GET IT
Times cited: 114 -
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies.
Clinical Cancer Research.
2002
Academic Article
GET IT
Times cited: 27 -
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of Clinical Oncology.
2002
Academic Article
GET IT
Times cited: 34 -
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Journal of Clinical Oncology.
2000
Academic Article
GET IT
Times cited: 10 -
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Journal of Clinical Oncology.
2000
Academic Article
GET IT
Times cited: 20 -
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Journal of Clinical Oncology.
2000
Academic Article
GET IT
Times cited: 77